• 한국전자파학회논문지
• /
• 제21권4호
• /
• pp.362-370
• /
• 2010

본 논문에서는 저온 동시 소성 세라믹(Low Temperature Co-fired Ceramic: LTCC) 기술을 이용하여 Wi-Fi와 WiMAX에 적용할 수 있는 무선 전단부(RF front-end) 모듈을 구현하였다. 무선 전단부 모듈은 3개의 LTCC 대역 통과 여파기와 FBAR 여파기, embedded된 정합 회로, Wi-Fi와 WiMAX 모드 선택용 SPDT 스위치, 송 수신택용 SPDT 스위치 그리고 대역 선택용 SP4T 스위치로 구성되어 있다. 모드 선택용 SPDT 스위치의 DC block 패시터를 실장하기 위한 패드 패턴에서 LTCC의 적층 구조의 특성으로 인해 0.2~0.3 pF의 값을 가지는 기생 성분이 생기게 된다. 이러한 기생 성분은 설계된 회로의 매칭을 틀어지게 만들어 결과적으로 모듈의 전기적 성능을 저하시킨다. 따라서 기생 커패시터 성분에 상응하는 칩 인덕터를 DC block 커패시터 패드 패턴과 병렬로 달아서 기생 성분을 상쇄하여 모듈의 특성을 최적화하였다. 제작된 무선 전단부 모듈은 내부 접지(inner GND) 3개 층을 포함한 12층으로 설계되었으며, 크기는 $6.0mm{\times}6.0mm{\times}0.728mm$이다.

• 대한방사성의약품학회지
• /
• 제7권2호
• /
• pp.105-111
• /
• 2021

⁸⁹Zr is a positron-emitting radioisotope, which has known as well-suited radioisotope for use in a monoclonal antibody-based imaging agent for immuno-PET. The purpose of this study was to quantitatively evaluate the diagnostic ability of general trastuzumab and thio-trastuzumab as HER2 positive receptors based on Df hexadentate iron chelator. Desferrioxamine-p-SCN (Df-Bz-NCS) and desferroixamine-maleimide (Df-Mal) were purchased from Macrocyclics (Dallas, TX, USA). The trastuzumab was purchased from Roche (Schweiz), and thio-trastuzumab was obtained from professor Hyo-Jeong Hong group (Kangwon National University). The radioisotope ⁸⁹Zr was produced by domestic purification system and KIRAMS using medical cyclotron (50 MeV, Scantronix). The conjugates of Df-trastuzumab and Df-thio-trastuzumab were prepared with Df-Bz-NCS and Df-Mal under basic aqueous solution (pH 8-9) at room temperature, respectively. The conjugates purified by PD-10 column were mixed with dried ⁸⁹Zr chloride. ⁸⁹Zr-labeled conjugates were purified and concentrated by Amicon ultra centrifugal filter. The preparation step and time of ⁸⁹Zr-labeled conjugates was shorted as 4 steps within 2 hours. ⁸⁹Zr-labeled conjugates showed the highly radiochemical purity of over 98%, and were very stable until 7 days by the analysis of radio-ITLC method. Each radio-labeled conjugates were also exhibited the highly stability in both PBS buffer and mouse serum. Immuno-PET imaging of ⁸⁹Zr-labeled conjugates in mice bearing gastric cancer xenograft tumors with HER2 expression showed high tumor uptake in the NCI-N87 HER2-expressing. However, ⁸⁹Zr-Df-Mal-thio-trastuzumab showed a relatively lower tumor-to-background ratio than ⁸⁹Zr-Df-Bz-trastuzumab, as well as whole-body distribution. In the results, ⁸⁹Zr-Df-Bz-trastuzumab was evaluated to have a relatively higher HER2 diagnostic ability than ⁸⁹Zr-Df-Mal-thio-trastuzumab.